{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100.0","upperLimit":"127.6","value":"-28.3"},{"groupId":"OG001","lowerLimit":"-69.1","upperLimit":"157.1","value":"20.0"},{"groupId":"OG002","lowerLimit":"-93.6","upperLimit":"11.6","value":"-40.4"},{"groupId":"OG003","lowerLimit":"-90.0","upperLimit":"114.3","value":"-70.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Day 1 1.5 hours post-dose - CD3+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100.0","upperLimit":"445.8","value":"-34.0"},{"groupId":"OG001","lowerLimit":"-62.6","upperLimit":"52.4","value":"-52.8"},{"groupId":"OG002","lowerLimit":"-95.7","upperLimit":"33.8","value":"-39.7"},{"groupId":"OG003","lowerLimit":"-98.9","upperLimit":"105.0","value":"-70.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 15 1.5 hours post-dose - CD3+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-87.0","upperLimit":"28.9","value":"-22.1"},{"groupId":"OG001","lowerLimit":"-50.6","upperLimit":"66.6","value":"7.0"},{"groupId":"OG002","lowerLimit":"-54.7","upperLimit":"25.8","value":"-8.7"},{"groupId":"OG003","lowerLimit":"-85.3","upperLimit":"46.3","value":"-36.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"title":"Day 1 1.5 hours post-dose - CD14+"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-91.7","upperLimit":"528.1","value":"-58.1"},{"groupId":"OG001","lowerLimit":"-67.5","upperLimit":"111.6","value":"-28.4"},{"groupId":"OG002","lowerLimit":"-78.7","upperLimit":"26.0","value":"-25.6"},{"groupId":"OG003","lowerLimit":"-68.3","upperLimit":"23.2","value":"-47.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"Day 15 1.5 hours post-dose - CD14+"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"Phosphorylated 4E-BP1 is a biomarker for inhibition of the mammalian target of rapamycin complex 1 (mTORC1). Phosphorylated 4E-BP1 was measured in stimulated monocytes via flow cytometry. MFI values were determined and converted to molecules of equivalent fluorescence label (MEFL) by normalizing against calibration beads. The biomarker evaluable population included all subjects who took at least one dose of study drug and had at least one non-missing pharmacodynamic (PD) assessment. Data is reported by T-cell subsets known as clusters of differentiation (CD).","dispersionType":"Full Range","groups":[{"description":"Participants with HCC received a daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"HCC 30 mg"},{"description":"Participants with HCC received a daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"HCC 45 mg"},{"description":"Participants with NET received a daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"NET 30 mg"},{"description":"Participants with NET received a daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"NET 45 mg"}],"paramType":"MEDIAN","populationDescription":"All biomarker evaluable participants who received treatment in Part B.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 1.5 hours post-dose and Day 15: 1.5 hours post-dose","title":"Part B: Percent Change From Baseline in p4E-BP1 in Monocytes in the HCC and NET Cohorts by Dose","type":"SECONDARY","unitOfMeasure":"Percent change in p4E-BP1"}